Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RRM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RRM2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site intact for enzymatic screening. |
View RRM2 Products |
| Gene Delivery | RRM2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View RRM2 Products |
| Benchmark Ab | Anti-RRM2 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and ELISA assays. |
View RRM2 Products |
| Validator | RRM2 siRNA Set Target-specific knockdown verification to confirm phenotype-to-genotype correlation. |
View RRM2 Products |
| Related Target A | RRM1 The large catalytic subunit of ribonucleotide reductase. Critical for dimer partner screening and holoenzyme assembly assays. |
View RRM1 Products |
| Related Target B | RRM2B (p53R2) p53-inducible ribonucleotide reductase small subunit. Essential for off-target selectivity and safety profiling. |
View RRM2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against RRM2B (p53R2) to prevent systemic toxicity | High-purity human RRM2 and RRM2B ortholog proteins strictly verified by mass spectrometry and sequence-validated. |
| In vitro enzymatic activity preservation for small molecule screening | High-activity recombinant RRM2 proteins expressed in native host systems with rigorous endotoxin and aggregation control. |
| Lack of standardized assay controls | Clinical benchmark antibodies and sequence-verified positive control plasmids included. |
| False positives in phenotype screening | Validated siRNA sets included for target knockdown and specificity correlation. |
Live RRM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RRM2 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein degraders (PROTACs) and combination regimens. As first-generation therapies like Triapine (3-AP) and COH29 reach the clinic, the next wave of R&D is targeting drug-resistant mutations and exploiting synthetic lethality in homologous recombination-deficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | NCI, Coherus, Academic Institutions | Solid Tumors, Hematological Malignancies | Enzymatic Inhibition Assay (Need highly active, pure recombinant RRM2 protein) |
| Targeted Degradation (PROTAC) | Biotech Startups, University Labs | Gemcitabine-Resistant Cancers | Ubiquitination & Degradation Assay (Need sequence-verified RRM2 for target binding) |
| RNA Therapeutics (siRNA/ASO) | Lorus Therapeutics, Custom RNA Developers | Advanced Solid Tumors | Target Knockdown Validation (Need validated RRM2 siRNA and Lentivirus controls) |